An Exploratory Maintenance Trial Evaluating the Effect of BI 655064 in Lupus Nephritis Patients Who Have Achieved a Meaningful Response Either at the End of 1293.10 or After an Induction Treatment Outside of 1293.10
Latest Information Update: 13 Sep 2023
At a glance
- Drugs BI 655064 (Primary)
- Indications Lupus nephritis
- Focus Therapeutic Use
- Sponsors Boehringer Ingelheim; Boehringer Ingelheim Pharma KG; Unilfarma
- 29 Jul 2021 Status changed from active, no longer recruiting to completed.
- 15 Jun 2021 Planned End Date changed from 4 Aug 2021 to 8 Aug 2021.
- 07 Jun 2021 Planned End Date changed from 8 Aug 2021 to 4 Aug 2021.